CANF vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CANF and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CANF and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company that trades in the US as an ADR on the NYSE American. Its platform is built on the A3 adenosine receptor (A3AR), a G-protein-coupled receptor that is highly expressed on inflammatory and cancer cells but has low expression in normal cells, which the company argues makes it a selective drug target across cancer, liver disease, and inflammatory conditions. Can-Fite has no approved products and generates essentially no product revenue; it is a research-and-development-stage business whose value rests entirely on its pipeline of small-molecule A3AR drug candidates and its ability to fund years of clinical trials. Its two lead candidates are Namodenoson, in Phase 3 for advanced liver cancer (hepatocellular carcinoma) with additional studies in MASH (a metabolic liver disease) and pancreatic cancer, and Piclidenoson, in a pivotal Phase 3 study for psoriasis.

Full CANF guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CANF drivers: Namodenoson liver-cancer (HCC) Phase 3 readout; Broader Namodenoson pipeline (MASH and pancreatic cancer).
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: This is a highly speculative micro-cap with concentrated, binary risk. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CANF if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CANF and MRNA guides.

CANF. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech, traditional valuation metrics such as P/E do not apply, because there are no earnings; what matters is cash runway, the probability and timing of clinical readouts, and dilution. The small cash balance, recurring losses, dependence on dilutive financing, and a large reverse split all point to significant liquidity pressure, so the investment case is a speculative, binary bet on trial outcomes rather than on any current financial performance.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, Jul 2026): CANF shows revenue / earnings Pre-revenue clinical-stage company with no approved products; it reports recurring net losses, not profits, net loss (2025) approximately $9.8 million (versus about $7.9 million in 2024), accumulated deficit approximately $176 million as of December 31, 2025, cash position approximately $5.5 million cash plus about $3.0 million short-term deposits at December 31, 2025; management indicated roughly twelve months of runway from that point, with more capital needed thereafter; MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

CANF and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CANF and MRNA exposure against your real portfolio. It is not an investment adviser.